痰热清注射液治疗社区获得性肺炎的疗效观察

Observation of Tanreqing injection （痰热清注射液） in the treatment of community-acquired pneumonia

目的 观察痰热清注射液治疗社区获得性肺炎（CAP）的临床疗效.方法 将139例CAP患者随机分为两组,对照组（67例）给予阿奇霉素0.5 g静脉滴注（静滴）,治疗组（72例）在对照组治疗基础上加用痰热清注射液20 ml静滴,均每日1次,7 d为1个疗程.观察患者治疗前后主要临床症状、体征、血白细胞计数（WBC）及分类、C-反应蛋白（CRP）、X线胸片变化情况,并记录不良反应发生情况.结果 治疗组临床症状、体征恢复时间较对照组明显缩短（P〈0.05或P〈0.01）;两组治疗后血WBC、中性粒细胞比例（N）及CRP较治疗前明显改善[对照组：WBC（6.5±4.0）×109/L比（12.7±4.2）×109/L,N 0.70±0.07比0.89±0.03,CRP（15.4±6.7）mg/L比（46.1±8.0）mg/L;治疗组：WBC（5.8±3.6）×109/L比（12.6±4.4）×109/L,N 0.69±0.06比0.89±0.03,CRP（8.3±4.6）mg/L比（44.9±8.1）mg/L,均P〈0.05],治疗组CRP较对照组改善更明显（P〈0.05）.X线胸片示治疗组炎症病灶全部吸收率明显高于对照组（34.7%比26.9%,P〈0.05）;治疗组总有效率明显高于对照组（95.8%比85.1%,P〈0.05）.两组均未见严重不良反应发生.结论 痰热清注射液治疗CAP患者临床症状缓解快、疗效满意,无明显不良反应发生.

Objective To observe the clinical efficacy of Tanreqing injection （痰热清注射液） in treating community-acquired pneumonia （CAP）. Methods One hundred and thirty-nine patients with CAP were randomly divided into two groups： the control （n = 67） and treatment （n= 72） groups. The former group received routine therapy with azithromycin 0.5 g intravenous drip once a day, while the treatment group receivedroutine therapy plus Tanreqing injection 20 ml intravenous drip once a day, a therapeutic course being 7 days. The clinical symptoms, physical signs, white blood cell （WBC） count and classification, C-reactive protein （CRP）, chest X-ray before and after therapy were observed, and the side effects were recorded. Results Compared with control group, the time of recovery of clinical symptoms and signs was shorter in the treatment group （P〈0.05 or P〈0.01）. The blood WBC, neutrophil （N）, CRP after treatment in two groups were improved compared with those before treatment [in control group： WBC （6.5 ±4.0）× 10^9/L vs. （12.7±4.2）× 10^9/L, N 0.70±0.07 vs. 0.89±0.03, CRP （15.4±6.7）mg/L vs. （45.1±8.0） mg/L; in treatment group： WBC （5.8±3.6）× 10^9/Lvs. （12.6±4.4）× 10^9/L, N 0.69±0.06 vs. 0.89±0.03, CRP （8.3±4.6） mg/L vs. （44.9±8.1） mg/L, all P〈0.05], and the improvement of CRP in treatment group was better than that in control group （P〈0. 05）. The chest X-ray showed the absorption rate of inflammation in treatment group was significantly higher than that in control group （34.7%vs. 26.9%, P〈0.05）. The total effective rate of treatment group was obviously higher than that of control group （95.8% vs. 85.1%, P〈0.05）. There was no severe adverse reaction in both groups. Conclusion Tanreqing injection can improve the symptoms and signs quickly and satisfactorily in the treatment of CAP, and cause no obvious adverse reaction.